CA Patent

CA2614334A1 — Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Assigned to Novartis AG · Expires 2007-02-08 · 19y expired

What this patent protects

The invention provides crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridine-3-yl-pyrimidin-2-ylamino)-benzamide of the formula (see above formula) The crystalline forms of the invention are useful in the manufacture of pharmaceutical…

USPTO Abstract

The invention provides crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridine-3-yl-pyrimidin-2-ylamino)-benzamide of the formula (see above formula) The crystalline forms of the invention are useful in the manufacture of pharmaceutical compositions.

Drugs covered by this patent

Patent Metadata

Patent number
CA2614334A1
Jurisdiction
CA
Classification
—
Expires
2007-02-08
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.